174671-46-6

URI: https://gptkb.org/entity/174671-46-6
GPTKB entity
Statements (34)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkbp:administeredBy oral
gptkbp:approvalYear 2014
gptkbp:ATCCode N05CM25
gptkbp:brand gptkb:Belsomra
gptkbp:CASNumber gptkb:174671-46-6
gptkbp:developedBy gptkb:Merck_&_Co.
gptkbp:eliminationHalfLife 12 hours
gptkbp:excretion urine
feces
gptkbp:hasInChIKey QOVJKBMQGXRZQQ-UHFFFAOYSA-N
gptkbp:hasMolecularFormula C23H23ClN6O2
gptkbp:hasSMILES CN1CCN(CC1)C(=O)C2=CC(=C(C=C2)C)N3N=CC=N3
gptkbp:hasUNII 7X9Q64V4A4
https://www.w3.org/2000/01/rdf-schema#label 174671-46-6
gptkbp:isApprovedDrug true
gptkbp:IUPACName [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
gptkbp:legalStatus Rx-only (US)
gptkbp:mechanismOfAction orexin receptor antagonist
gptkbp:metabolism gptkb:liver_(CYP3A)
gptkbp:molecularWeight 450.92 g/mol
gptkbp:name gptkb:Suvorexant
gptkbp:pregnancyCategory C (US)
gptkbp:PubChem_CID CHEMBL2105758
24964624
DB09025
gptkbp:routeOfAdministration oral
gptkbp:sideEffect fatigue
headache
somnolence
abnormal dreams
gptkbp:usedFor treatment of insomnia
gptkbp:bfsParent gptkb:tavaborole
gptkbp:bfsLayer 6